KPV
Three amino acids from the tail of alpha-MSH. Interferes with NF-kB to turn down inflammatory signalling at the source. Orally active in animal models.
BPC-157
Fifteen amino acids derived from gastric juice. Promotes blood vessel growth and tissue repair. The most researched peptide in this category, almost entirely in animals.
Side-by-Side Comparison
Turns down the production of inflammatory cytokines by interfering with NF-kB, an upstream master switch. Best mechanistic fit when the problem is an overactive inflammatory response.
Promotes angiogenesis and repair of damaged tissue. Best mechanistic fit when the problem is physical injury to the gut lining, such as ulcers or NSAID damage.
No controlled human clinical trial of KPV has been published for any condition.
A 2025 systematic review found 36 studies through June 2024: 35 preclinical and 1 clinical. The one human study is a 16-patient retrospective knee-pain series with no control group.
Consistently reduced inflammation and disease severity across multiple independent rodent colitis models, including with oral dosing.
Hundreds of animal studies across gut, tendon, ligament, muscle, nerve, and bone, from many laboratories, with consistent results.
Small enough to be taken up directly by intestinal cells through the PepT1 transporter, so it does not need to survive digestion intact. This is the main reason it is interesting for gut conditions specifically.
The arginine salt form is marketed as orally stable and is the usual choice for gut issues. Human absorption data is not published.
Placed in FDA Category 2 in 2023. On 23 July 2026 an FDA advisory committee voted 8 to 6 to recommend it for the permitted 503A list. That vote is advisory and changes nothing until FDA rulemaking completes.
Same trajectory: Category 2 in 2023, removed from Category 2 in April 2026, recommended by the same advisory committee on the same day by the same 8 to 6 margin.
NF-kB is a core immune signalling pathway. What suppressing it long-term does in a human body has not been studied. It can also mask disease activity, which complicates monitoring.
Promoting new blood vessel growth is helpful for healing and is also something tumours require. No human study has assessed this risk.
Very cheap to synthesize at three amino acids. Usually sold as oral capsules.
Widely available in both injectable and oral forms.
The mechanistic split between these two is genuinely clean, which makes the comparison easy to reason about and unusually easy to over-trust.
**KPV** works on inflammation. It interferes with NF-kB, the switch that turns on inflammatory gene expression, so it is the better mechanistic fit when your problem is an immune system attacking your gut, as in inflammatory bowel disease.
**BPC-157** works on damage. It promotes blood vessel growth and tissue repair, so it is the better fit when the problem is physical injury to the gut lining, such as ulcers or damage from long-term NSAID use.
Now the part that matters more than the split: neither has a single controlled human trial. Not one. KPV has never been tested in a controlled human study for any condition, and a 2025 systematic review of the entire BPC-157 literature found 35 of 36 studies were in animals. Rodent gut models have a particularly poor record of predicting human results, which is why several drugs that cured mouse colitis did nothing in people.
So the honest answer is: pick based on mechanism if you are going to try one, but treat both as experiments. If you have diagnosed inflammatory bowel disease, neither is a substitute for treatment that actually has outcome data, and untreated IBD causes cumulative permanent damage while you experiment.
Which Is Right for You?
- Your problem is inflammatory rather than structural
- You have inflammatory bowel disease and want to try something alongside real treatment
- You want oral dosing with animal evidence behind that specific route
- You are also interested in the topical anti-inflammatory use
- You want the cheaper option
- Your problem is tissue damage: ulcers, NSAID injury, a healing wound
- You also have a musculoskeletal injury you want to target
- You want the compound with the largest body of animal research behind it
- You want the option of injecting near a specific injury site
Important Note
This comparison is for educational purposes only and should not replace medical advice. The best medication for you depends on your individual health profile, medical history, and personal circumstances. Always consult with a healthcare provider who can evaluate your specific situation before starting any medication.
Frequently Asked Questions
Can you take KPV and BPC-157 together?
People do, on the theory that one handles inflammation while the other handles repair, which is mechanistically coherent. No study has examined the combination in humans or animals, so there is no evidence on either added benefit or interaction. Combining two compounds that individually have no controlled human data does not produce evidence, it just doubles the unknowns.
Which is better for IBD, KPV or BPC-157?
On mechanism, KPV is the better fit, because inflammatory bowel disease is driven by inflammation and KPV acts directly on the inflammatory signalling pathway. On evidence, neither has any: no controlled human trial exists for either compound in IBD. Approved IBD treatments have decades of outcome data, and untreated disease causes cumulative bowel damage, so neither peptide should replace real treatment.
Is KPV or BPC-157 legal?
Both are in the same unsettled position. Each was placed in FDA Category 2 in 2023, and on 23 July 2026 an FDA advisory committee voted 8 to 6 to recommend both for the permitted 503A compounding list. Those votes are advisory and non-binding. Changing their legal status requires FDA rulemaking, which typically takes 12 to 24 months, so nothing has actually changed yet.
Do I need to inject either of these?
Not necessarily. KPV is small enough to be absorbed directly by intestinal cells, which is why it is usually sold as oral capsules and why the animal evidence used oral dosing. BPC-157 is commonly taken orally as the arginine salt form for gut issues, and injected when the target is a musculoskeletal injury. For gut problems specifically, oral is the sensible route for both.
Which one has more research?
BPC-157, by a wide margin, with hundreds of animal studies across many tissue types from many independent laboratories. But volume of animal research is not the same as evidence of human benefit. A 2025 systematic review found that of 36 BPC-157 studies published through June 2024, 35 were preclinical and one was clinical, and concluded the compound should not be recommended clinically until human trials exist.